Reshaping immunometabolism in the tumour microenvironment to improve cancer immunotherapy

The evolving understanding of cellular metabolism has revealed a the promise of strategies aiming to modulate anticancer immunity by targeting metabolism. The combination of metabolic inhibitors with immune checkpoint blockade (ICB), chemotherapy and radiotherapy may offer new approaches to cancer treatment. However, it remains unclear how these strategies can be better utilized despite the complex tumour microenvironment (TME). Oncogene-driven metabolic changes in tumour cells can affect the TME, limiting the immune response and creating many barriers to cancer immunotherapy. These changes also reveal opportunities to reshape the TME to restore immunity by targeting metabolic pathways. Further exploration is required to determine how to make better use of these mechanistic targets. Here, we review the mechanisms by which tumour cells reshape the TME and cause immune cells to transition into an abnormal state by secreting multiple factors, with the ultimate goal of proposing targets and optimizing the use of metabolic inhibitors. Deepening our understanding of changes in metabolism and immune function in the TME will help advance this promising field and enhance immunotherapy.

Automated summary

The evolving understanding of cellular metabolism has revealed the promise of targeting metabolism to modulate anticancer immunity. The combination of metabolic inhibitors with immune checkpoint blockade, chemotherapy, and radiotherapy may offer new approaches to cancer treatment. However, there is still a need for further exploration to optimize the use of these strategies despite the complex tumour microenvironment.